跳至主要内容
临床试验/NCT05536466
NCT05536466尚未招募不适用

The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine

Radboud University Medical Center0 个研究点目标入组 8 人开始时间: 2022年9月30日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
8
主要终点
AUC of doravirine

研究概览

简要总结

a multicentre phase IV study to collect evidence that a doravirine-based regimen can be safely and effectively administered to virologically suppressed HIV-infected patients undergoing bariatric suregery.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • HIV-infected
  • VL suppressed <40c/ml for at least 6 months, blips are allowed
  • planned to have bariatric surgery (gastric bypass or gastric sleeve)
  • Able to sign informed consent
  • Age > or equal to 18 years
  • Using doravirine for at least 4 weeks prior to BS with VL < 40 copies/mL prior to the surgery

排除标准

  • History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study or interfere with the subject's participation
  • Requires or is anticipated to require any of the prohibited medications known to contradict/interact with doravirine
  • Has significant hypersensitivity or other contraindication to doravirine
  • Creatinine clearance <40 ml/min
  • Severe liver dysfunction (Diagnosed liver cirrhosis: Child-Pugh C)
  • Pregnancy or planning to be pregnant during first 6 months postbariatric surgery.

结局指标

主要结局

AUC of doravirine

时间窗: 24 hours

area under the curve, doravirine

次要结局

  • HIV viral load(24 weeks)
  • adverse events(24 weeks)

研究者

申办方类型
Other
责任方
Sponsor

相似试验